PMID- 23499696
OWN - NLM
STAT- MEDLINE
DCOM- 20131105
LR  - 20220408
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 705
IP  - 1-3
DP  - 2013 Apr 5
TI  - Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting 
      activation of NF-kappaB and MAPKs signal pathways.
PG  - 79-85
LID - S0014-2999(13)00117-9 [pii]
LID - 10.1016/j.ejphar.2013.02.021 [doi]
AB  - Emodin is an anthraquinone derivative from the Chinese herb Radix et Rhizoma 
      Rhei. It has been reported that emodin possesses a number of biological 
      properties, such as anti-inflammatory, anti-virus, anti-bacteria, anti-tumor, and 
      immunosuppressive properties. However, the effect of emodin on mastitis is not 
      yet known. The aim of this study was to investigate whether emodin has protective 
      effect against lipopolysaccharide (LPS)-induced mastitis in a mouse model. The 
      mouse model of mastitis was induced by injection of LPS through the duct of 
      mammary gland. Emodin was administered intraperitoneally with the dose of 1, 2, 
      and 4 mg/kg respectively 1h before and 12h after induction of LPS. Emodin 
      significantly reduced infiltration of neutrophilic granulocyte, activation of 
      myeloperoxidase (MPO), concentration of tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6), mRNA expression levels of 
      TNF-alpha, IL-1beta and IL-6, which were increased in LPS-induced mouse mastitis. In 
      addition, emodin influenced nuclear factor kappa-B signal transduction pathway by 
      inhibiting activation of nuclear transcription factor-kappaB (NF-kappaB) p65 and 
      degradation inhibitor of NF-kappaB alpha (IkappaBalpha), and emodin also influenced mitogen 
      activated protein kinases signal transduction pathway by depression activation of 
      p38, extracellular signal-regulated kinase (ERK), and c-jun NH2-terminal kinase 
      (JNK). In conclusion, these results indicated that emodin could exert beneficial 
      effects on experimental mastitis induced by LPS and may represent a novel 
      treatment strategy for mastitis.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Li, Depeng
AU  - Li D
AD  - Department of Clinical Veterinary Medicine, College of Animal Science and 
      Veterinary Medicine, Jilin University, Changchun, Jilin Province 130062, People's 
      Republic of China.
FAU - Zhang, Naisheng
AU  - Zhang N
FAU - Cao, Yongguo
AU  - Cao Y
FAU - Zhang, Wen
AU  - Zhang W
FAU - Su, Gaoli
AU  - Su G
FAU - Sun, Yong
AU  - Sun Y
FAU - Liu, Zhicheng
AU  - Liu Z
FAU - Li, Fengyang
AU  - Li F
FAU - Liang, Dejie
AU  - Liang D
FAU - Liu, Bo
AU  - Liu B
FAU - Guo, Mengyao
AU  - Guo M
FAU - Fu, Yunhe
AU  - Fu Y
FAU - Zhang, Xichen
AU  - Zhang X
FAU - Yang, Zhengtao
AU  - Yang Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130313
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - KA46RNI6HN (Emodin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Cytokines/genetics/metabolism
MH  - Emodin/*pharmacology/therapeutic use
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Lipopolysaccharides
MH  - MAP Kinase Signaling System/*drug effects
MH  - Male
MH  - Mastitis/chemically induced/drug therapy/*metabolism/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/*antagonists & inhibitors
MH  - Peroxidase/metabolism
MH  - RNA, Messenger/metabolism
EDAT- 2013/03/19 06:00
MHDA- 2013/11/06 06:00
CRDT- 2013/03/19 06:00
PHST- 2012/10/05 00:00 [received]
PHST- 2013/02/04 00:00 [revised]
PHST- 2013/02/07 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/11/06 06:00 [medline]
AID - S0014-2999(13)00117-9 [pii]
AID - 10.1016/j.ejphar.2013.02.021 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2013 Apr 5;705(1-3):79-85. doi: 10.1016/j.ejphar.2013.02.021. 
      Epub 2013 Mar 13.